Tonix Pharmaceuticals Holding Corp. (TNXP)
| Market Cap | 233.08M -17.4% |
| Revenue (ttm) | 29.10M +196.0% |
| Net Income | -159.67M |
| EPS | -12.49 |
| Shares Out | 17.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 490,503 |
| Open | 13.52 |
| Previous Close | 13.56 |
| Day's Range | 13.30 - 13.98 |
| 52-Week Range | 9.40 - 33.22 |
| Beta | 1.69 |
| Analysts | Strong Buy |
| Price Target | 42.40 (+211.99%) |
| Earnings Date | Aug 10, 2026 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingu... [Read more]
Financial Performance
In 2025, TNXP's revenue was $13.11 million, an increase of 29.85% compared to the previous year's $10.09 million. Losses were -$124.02 million, -4.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TNXP stock is "Strong Buy." The 12-month stock price target is $42.4, which is an increase of 211.99% from the latest price.
News
Tonix Pharmaceuticals Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference
Recent results show strong uptake of a new fibromyalgia therapy, with net sales tripling quarter-over-quarter and expanded market access. The pipeline includes a monoclonal antibody for Lyme disease prevention entering phase II in 2025 and a phase II study for major depression, both with results expected by 2028.
Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James
Raymond James raised the firm’s price target on Tonix Pharmaceuticals (TNXP) to $27 from $25 and keeps a Strong Buy rating on the shares. In Tonmya’s second full quarter on…
Tonix Pharmaceuticals Holding Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue growth driven by Tonmya's successful launch, expanded market access, and strong refill dynamics, while pipeline programs advanced with pivotal studies in MDD and Lyme disease prevention. Cash runway extends into early Q2 2027.
Tonix Pharmaceuticals Holding Earnings release: Q2 2026
Tonix Pharmaceuticals Holding released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Tonix Pharmaceuticals Holding Quarterly report: Q2 2026
Tonix Pharmaceuticals Holding has published its Q2 2026 quarterly earnings report on August 10, 2026.
Tonix Pharmaceuticals Holding Slides: Q2 2026
Tonix Pharmaceuticals Holding has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 13...
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals receives Type C meeting minutes from FDA for TNX-4800
Tonix Pharmaceuticals (TNXP) announced the receipt of official minutes from the Type C meeting with the FDA to discuss the company’s plans for an adaptive Phase 2 field study of…
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals Holding Slides: Corporate presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on July 20, 2026.
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2026.
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak
Tonix Pharmaceuticals announces managed Medicare agreement for Tonmya
Tonix Pharmaceuticals (TNXP) announced a managed Medicare agreement for Tonmya, adding approximately 9M Medicare lives. The new agreement will go into effect on January 1, 2027. On top of two…
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.)
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Tonix Pharmaceuticals enrolls first patient in HORIZON study
Tonix Pharmaceuticals (TNXP) announced that the first patient has been enrolled in HORIZON, a potentially pivotal Phase 2 study evaluating TNX-102 SL 5.6 mg as a first-line monotherapy in adults…
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults...
Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Tonix Pharmaceuticals (TNXP) with a Strong Buy rating and $26 price target TNX-4800 has a strong fit for high-propensity Lyme-prevention populations, and the passiv...
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals secures second commercial agreement for Tonmya
Tonix Pharmaceuticals (TNXP) announced an agreement with a second group purchasing organization, or GPO, that provides coverage for Tonmya to an additional approximately 17M U.S. commercial lives, rep...
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commerc...